UK Biomedical Cluster, Pfizer Partner to Translate Basic Science into Rare Disease Treatments | GenomeWeb

NEW YORK (GenomeWeb) – The Global Medical Excellence Cluster (GMEC), a UK non-profit focused on advancing translational research, has inked an agreement with Pfizer to use molecular and genomic technologies to develop medicines for treating rare diseases.

Under the five-year initiative, investigators at GMEC's partnering universities will work with Pfizer scientists in joint programs aiming to translate basic research into new drugs for treating rare diseases, GMEC said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: sequencing technique to uncover plant disease-resistance genes, and more.

In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.

NantKwest's Patrick Soon-Shiong received some $148 million in compensation in 2015.

With sequencing moving toward applications, Illumina CEO Francis deSouza says his company has even more to offer, Fast Company reports.